Next, we exposed MLL-rearranged ALL cell lines SEM and KOPN8 to the MEK inhibitors (Selumetinib, MEK162 and Trametinib) and determined p-ERK and p-MEK levels by immunoblotting (Figure 4). This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.